tlooto
Sign up
SCIESCOPUSQ2

Drugs in Context

BIOEXCEL PUBL LTD, Sweden

Drugs in Context is an academic journal published by BIOEXCEL PUBL LTD (Sweden). Identifiers: ISSN 1745-1981, eISSN 1740-4398. Indexed in SCIE, SCOPUS. Metrics: JIF 2.8, CiteScore 5.0, SJR 0.775, SNIP 0.96. tlooto lists 655 papers from this journal.

CiteScore

5.00

Scopus citation metric

SJR

0.775

SCImago rank

SNIP

0.96

Source normalized impact

Percentage rank

-

JIF percentile rank

Journal profile

ISSN
1745-1981
eISSN
1740-4398
Abbreviation
DRUGS CONTEXT
Publisher
BIOEXCEL PUBL LTD
Country
Sweden

Web of Science categories

No Web of Science category data available.

Scopus ASJC categories

2700 General Medicine3004 Pharmacology

Papers in this journal

Recent papers

  1. Optimizing care and quality indicators in the management of patients with acute ischaemic heart disease and atherothrombotic stroke: measuring to improve

    2026 · 1 citations

  2. SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications

    2026

  3. Biologics-induced cutaneous pseudolymphomas: a narrative review with an illustrative case of brodalumab-induced pseudolymphoma

    2026 · 1 citations

  4. Clinical profile, management and outcomes of patients taking dual pathway inhibition for cardiovascular protection in clinical practice in Latin America. Data from the XATOA registry

    2026

  5. Recombinant human erythropoietin therapy in patients with cancer: efficacy, risks and the controversy of EpoR expression

    2026

Most cited papers

  1. How to manage Pseudomonas aeruginosa infections

    2018 · 667 citations

  2. Antidepressant efficacy and side-effect burden: a quick guide for clinicians

    2015 · 444 citations

  3. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease

    2018 · 203 citations

  4. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges

    2019 · 181 citations

  5. Aducanumab: evidence from clinical trial data and controversies

    2021 · 164 citations